This is a summary of the European public assessment report (EPAR) for Docetaxel Kabi. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing ... European Medicines Agency, 1 week ago
1 images for "fresenius kabi oncology"
Sales decline 69.90% to Rs 45.27 crore Net loss of Fresenius Kabi Oncology reported to Rs 63.63 crore in the quarter ended December 2013 as against net profit of Rs 48.36 crore during the previous quarter ended December 2012. Sales declined 69.90% to Rs 45.27 ...Business Standard, 2 months ago
MUMBAI: Shareholder advisory firms have raised concerns over the recent delisting move by certain companies and the route adopted by them to comply with norms. These firms have asked market regulator Sebi to streamline the delisting process which, ...Times of India, 2 weeks ago ASTRAZENECA : Companies skirt delisting norms: Advisory firms 4 Traders, 2 weeks ago AstraZeneca set to pop delist pill Calcutta Telegraph, 1 month ago
on your WebpageAdd Widget >Get your members hooked!